Adriana Malone is an Oncology physician affiliated with Tisch Cancer Institute. OpenAlex indexes 63 publications with 1,726 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year20253 payments
- GlaxoSmithKline, LLC.Program year20251 payment
- Merck Sharp & Dohme LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
22.6%Bile Acid11.3%Ursodiol100%Part D<11 patientsProton pump inhibitor6.3%Pantoprazole Sodium100%Part D<11 patients+ 1 more class in this area
Anti-infectives
21.6%Azole Antifungal9.6%Posaconazole100%Part D<11 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor4.3%Valacyclovir100%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
15.9%BCL-2 Inhibitor6.6%Venclexta100%Part D<11 patientsKinase inhibitor5%Jakafi100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- CD19 CAR T‐Cell Therapy for Primary Mediastinal Large B‐Cell Lymphoma: A CIBMTR Analysis
American Journal of Hematology
2025 - Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101
Transplantation and Cellular Therapy
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Matthew Galsky, MD
Tisch Cancer Institute
Santiago Thibaud, MD
Tisch Cancer Institute
James Ferrara, MD
Tisch Cancer Institute
Deniz Demircioğlu
Tisch Cancer Institute
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”